SC
HRMY icon

SummitTX Capital’s Harmony Biosciences HRMY Stock Holding History

SummitTX Capital’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$289K Sell
7,931
-2,763
-26% -$87.2K 0.01% 682
2026
Q1 		$300K Buy
+10,694
New +$351K 0.01% 644

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SummitTX Capital's HRMY Position: Q2 2026 in Review

SummitTX Capital reduced its Harmony Biosciences (HRMY) stake by 26% in Q2 2026, selling an estimated $87.2K and leaving 7,931 shares worth $289K. The position accounts for 0.01% of the portfolio, ranked #682.

SummitTX Capital first reported a position in HRMY in Q1 2026 and has held it in 2 quarters since. The position peaked at $300K in Q1 2026. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • SummitTX Capital held 7,931 shares of Harmony Biosciences worth $289K as of Q2 2026.
  • SummitTX Capital sold 2,763 Harmony Biosciences shares in Q2 2026, an estimated $87.2K.
  • Harmony Biosciences made up 0.01% of SummitTX Capital's portfolio in Q2 2026, its #682 holding.
  • SummitTX Capital first reported a position in Harmony Biosciences in Q1 2026 and has held it in 2 quarters since.
  • SummitTX Capital's Harmony Biosciences position peaked at $300K in Q1 2026.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.